GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (FRA:I5X) » Definitions » Cyclically Adjusted Price-to-FCF

Precigen (FRA:I5X) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Precigen Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Precigen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Precigen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Cyclically Adjusted Price-to-FCF Chart

Precigen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Precigen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Precigen's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Precigen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precigen's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Precigen's Cyclically Adjusted Price-to-FCF falls into.


;
;

Precigen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Precigen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Precigen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.053/134.9266*134.9266
=-0.053

Current CPI (Mar. 2025) = 134.9266.

Precigen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.167 100.684 -0.224
201509 0.395 100.392 0.531
201512 0.074 99.792 0.100
201603 -0.060 100.470 -0.081
201606 -0.137 101.688 -0.182
201609 -0.195 101.861 -0.258
201612 -0.229 101.863 -0.303
201703 -0.244 102.862 -0.320
201706 -0.261 103.349 -0.341
201709 -0.254 104.136 -0.329
201712 -0.335 104.011 -0.435
201803 -0.258 105.290 -0.331
201806 -0.258 106.317 -0.327
201809 -0.249 106.507 -0.315
201812 -0.325 105.998 -0.414
201903 -0.317 107.251 -0.399
201906 -0.272 108.070 -0.340
201909 -0.205 108.329 -0.255
201912 0.228 108.420 0.284
202003 -0.174 108.902 -0.216
202006 -0.085 108.767 -0.105
202009 -0.103 109.815 -0.127
202012 -0.083 109.897 -0.102
202103 -0.076 111.754 -0.092
202106 -0.037 114.631 -0.044
202109 -0.082 115.734 -0.096
202112 -0.077 117.630 -0.088
202203 -0.093 121.301 -0.103
202206 -0.041 125.017 -0.044
202209 -0.128 125.227 -0.138
202212 -0.073 125.222 -0.079
202303 -0.075 127.348 -0.079
202306 -0.059 128.729 -0.062
202309 -0.065 129.860 -0.068
202312 -0.062 129.419 -0.065
202403 -0.068 131.776 -0.070
202406 -0.094 132.554 -0.096
202409 -0.077 133.029 -0.078
202412 -0.030 133.157 -0.030
202503 -0.053 134.927 -0.053

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Precigen  (FRA:I5X) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Precigen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Precigen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Precigen Business Description

Industry
Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen Headlines

No Headlines